A thrombin receptor function for platelet glycoprotein Ib–IX unmasked by cleavage of glycoprotein V

  1. Vanitha Ramakrishnan*,,
  2. Francis DeGuzman*,
  3. Ming Bao*,
  4. Scott W. Hall,
  5. Lawrence L. Leung, and
  6. David R. Phillips*
  1. *COR Therapeutics, Inc., South San Francisco, CA 94080; and Division of Hematology, Stanford University School of Medicine, Palo Alto, CA 94305
  1. Edited by Philip W. Majerus, Washington University School of Medicine, St. Louis, MO, and approved November 29, 2000 (received for review October 26, 2000)

Abstract

Glycoprotein (GP) V is a major substrate cleaved by the protease thrombin during thrombin-induced platelet activation. Previous analysis of platelets from GP V-null mice suggested a role for GP V as a negative modulator of platelet activation by thrombin. We now report the mechanism by which thrombin activates GP V −/− platelets. We show that proteolytically inactive forms of thrombin induce robust stimulatory responses in GP V null mouse platelets, via the platelet GP Ib–IX–V complex. Because proteolytically inactive thrombin can activate wild-type mouse and human platelets after treatment with thrombin to cleave GP V, this mechanism is involved in thrombin-induced platelet aggregation. Platelet activation through GP Ib–IX depends on ADP secretion, and specific inhibitors demonstrate that the recently cloned P2Y12 ADP receptor (Gi-coupled ADP receptor) is involved in this pathway, and that the P2Y1 receptor (Gq-coupled ADP receptor) may play a less significant role. Thrombosis was generated in GP V null mice only in response to catalytically inactive thrombin, whereas thrombosis occurred in both genotypes (wild type and GP V null) in response to active thrombin. These data support a thrombin receptor function for the platelet membrane GP Ib–IX–V complex, and describe a novel thrombin signaling mechanism involving an initiating proteolytic event followed by stimulation of the GP Ib–IX via thrombin acting as a ligand, resulting in platelet activation.

Footnotes

  • To whom reprint requests should be addressed at: COR Therapeutics, Inc., 256 East Grand Avenue, South San Francisco, CA 94080. E-mail: vramakrishnan{at}corr.com.

  • This paper was submitted directly (Track II) to the PNAS office.

  • See commentary on page 1330.

  • Abbreviations:
    GP,
    glycoprotein;
    GP V f1,
    cleaved GP V;
    vWf,
    von Willebrand factor;
    PAR,
    protease-activated receptor;
    CHO,
    Chinese hamster ovary;
    DIP-,
    diisopropylphospho-;
    DFP,
    diisopropyl fluorophosphate;
    WP,
    washed platelets;
    wt,
    wild type;
    PGI2,
    prostacyclin;
    PGE1,
    prostaglandin E1
« Previous | Next Article »Table of Contents